© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
June 19th 2021, 12:00pm
The report gives a more holistic picture of a highly studied by little understood issue in multiple sclerosis.
June 17th 2021, 8:00pm
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
June 17th 2021, 6:10pm
Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.
June 17th 2021, 6:00pm
A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.
June 11th 2021, 7:00pm
The study authors hope their findings inform future interventions whose goal is to minimize the comorbidity burden of adults with multiple sclerosis (MS), thereby improving their quality of life and ultimate health outcomes.
June 9th 2021, 7:30pm
Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.
June 5th 2021, 12:00pm
June 3rd 2021, 2:45pm
The new study identified altered microRNA (miRNA) in gray matter lesions, which could provide a new important marker of multiple sclerosis (MS) progression.
May 29th 2021, 11:18am
Patient social cognition remained stable over 3 years, but its correlation with structural damage in the brain changed over time.
May 27th 2021, 2:00pm